Rheumnow Podcast

This year at ACR24, the RheumNow faculty and reporters were prolific, generating 800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days!  You can best review and learn ACR 2024 by A) Rheumatology Roundup; b) TOPIC Panel podcasts; and c) Topic podcasts.

This weeks notable citations on RheumNow.com

Discover the latest advancements in targeting the IL-17 pathway from the ACR Annual Meeting! This expert-led panel will delve into groundbreaking research and therapeutic strategies for managing rheumatic diseases.

Join us for an in-depth discussion about the ACR Annual Meeting! This expert panel will explore the latest research and clinical applications of JAK and TYK inhibitors in managing rheumatic diseases.

Stay informed about the cutting-edge therapies shaping the future of rheumatology care.

Dr. Janet Pope
London, Ontario

Dr. David Liew
Melbourne

Dr. Michael Putman
Milwaukee

Panelists: Dr. Jonathan Kay, Dr. Jiha Lee, Dr. Eric Dein and Dr. Jeffrey Spark

Tune in for an engaging discussion at the ACR Annual Meeting! This expert panel will explore the latest breakthroughs and trends in Psoriatic Arthritis(PsA) research and management, providing actionable insights for clinicians and researchers.

Highlight presentations from ACR 2024 in Washington, DC
Covered abstracts include:
- Dr. Kavanaugh
1679 Amplified & biomarkers
0082 Enthesitis Pathology & IL-23
1553 TLR 7/8 inhibitors in SLE
995 Carbon footprint to injectables
L20 ARTHUR DIANA Automated US
1132 VEGA (Combo Rx – see also 2640, 1460, 1393)
1745 Statin use in Oral Surveillance

- Dr. Cush
458 Seronegative RA fate
L19 Emapalumab in Stills disease
ACR 2024 updated guidelines on lupus nephritis
2580 Ianalumab in SLE
2259 Anti-Obesity Meds in RA
2657 Mortality with starting/stopping steroids
0774  TAPIR study in GCA
1697  PMR MODE study

Join us as we dive into expert insights from the ACR Annual Meeting! This special panel will focus on the latest research and advancements in Spondyloarthritis (SpA), featuring thought leaders in the field.
Dr. Marina Magrey
Cleveland
Dr. Lihi Eder
Toronto
Dr. Sheila Reyes
Phillipines
Dr. Adela Castro
Memphis

A New ACR
Cancer Survival in RA
"Changing Mindsets about Methotrexate Side Effects"
Control RA, Build Stronger Bones
Cumulative Steroid Use and Cardiovascular Events
Disease Activity in RA-ILD
Do TNFis and JAKis Prevent Cancer!?
Estimating Inflammation, Damage and Patient Distress
Finding the Right Combination Therapy in RA
Implantable Vagus Nerve Stimulator for RA
Is Frequent Lab Monitoring Necessary?
Long Term Follow up from APIPPRA
Metabolic Dysregulation and RA Interstitial Lung Disease
Native Americans with RA Die Young
Paraoxonase-1: Possible Biomarker for Progression to RA
Pred Softly: Steroids
Predicting Flares in Rheumatoid Arthritis
RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?
RA Treatment Adherence: Is decision making really shared?
RA: One JAK to Rule Them All?
Sonelokimab in PsA: Phase 2 Data
Treat-to-Target Improves Fertility in Women with RA
Treatment Considerations for RA-ILD
Treatment Strategies in RA
Use of AI in Hand Ultrasound Scoring
Vaccine Responses:The DMARD Counts
What's New in Relapsing Polychondritis?
What's The State of Biosimilars?

A New ACR
Anti IL-17 on Entheseal Biopsy in PsA
axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure
Best Things I Saw Today in PsA
Cycling vs Switching after TNFi Failure in axSpA
Improvements in Pain and Fatigue in Bimekizumab
Long-term Safety Profile of Bimekizumab in axSpA and PsA
Sonelokimab in PsA: Phase 2 Data
Treating SpA

A New ACR
Best Things I Saw Today in PsA
Do TNFis and JAKis Prevent Cancer!?
Hold or continue JAKi and IL-17 when receiving COVID boosters?
JAK-pot! How fast do DMARDs work?
JAKi Studies at ACR
Poly-treatment of Polymyalgia Rheumatica?
RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?
RA: One JAK to Rule Them All?
SELECT-GCA: Efficacy and Safety of Upadacitinib
"SELECT-GCA: Upadacitinib in Giant Cell Arteritis"
SELECTing the right patients: upadacitinib in GCA
So really, are JAKs Safe?
Summary of JAKi Studies
The Case for JAKi in PMR
The Real Value of JAKi is Beyond RA
When, What and How Long to Treat GCA & PMR
Worried about CV Risk and JAKi? What about the Steroids?